Novo Nordisk's Defining Week: A Failed Trial, a Legal Cloud, and a Head-to-Head With Eli Lilly
Published on 08/02/2026 at 11:11 | Redaktion boerse-global.de
The Danish pharmaceutical giant enters Wednesday's earnings report carrying more baggage than it has in years. A failed late-stage trial, a lingering securities lawsuit, and an intensifying pill war with its biggest rival have all converged on a single trading day — and investors are bracing for volatility across the entire GLP-1 sector.
The ZEUS Setback and Its True Weight
The trouble began on the last trading day of July, when Novo Nordisk disclosed that its experimental cardiovascular drug Ziltivekimab had missed its primary endpoints in the Phase-3 ZEUS study. The stock shed 8.48 percent to close at EUR 40.90, leaving the shares 25.45 percent below the 52-week high of EUR 54.86 reached back in January.
The mechanics of the failure deserve some precision. The drug did hit its biological target, inhibiting the IL-6 signaling pathway as designed. But against placebo, it showed no advantage on major adverse cardiovascular events. That distinction matters: the setback does not touch the commercial franchise of Wegovy or Ozempic, both of which continue to sell without interruption.
Still, the strategic implications are significant. Analysts had pegged Ziltivekimab's potential peak sales at more than $10 billion annually — a figure that represented Novo's best hope of diversifying beyond its diabetes and obesity dependence. That growth avenue has now vanished, at least for the foreseeable future.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Wall Street's reaction has been notably split. UBS analyst Matthew Weston struck a bearish tone, noting his firm had modeled roughly $3 billion of the drug's expected peak sales — about 60 percent of the consensus estimate — into its projections. Ziltivekimab accounted for only 1.7 percent of Novo's net present value, Weston calculated, yet he still expects the market reaction to run two to three times larger than the pure valuation impact. His reasoning: the failure amplifies pressure on the broader research pipeline.
Mizuho's Jared Holz called the early data disappointing, warning it could weigh on sentiment across Novo's entire pipeline beyond the weight-loss franchise. On the other side, some observers view the sell-off as overdone. Of the 26 analysts covering the stock, 18 rate it a "Hold," and the average price target implies upside of 4.45 percent from pre-sell-off levels. The counterargument: Ziltivekimab was always a modest piece of the portfolio.
A Report That Answers More Than the Chart Can
Wednesday's interim results for the first half of 2026 arrive with unusual weight. The report lands on the same day Eli Lilly publishes its own numbers, setting up a direct comparison in the oral GLP-1 arena that has become the sector's fiercest battleground.
The oral Wegovy tablet, launched in January 2026, generated $2.26 billion in revenue in its first quarter and reached over one million patients. Eli Lilly's rival pill, Foundayo, entered the market in April. Prescription data through the end of July shows Novo still ahead: roughly 171,700 weekly scripts for the Wegovy tablet versus about 29,388 for Foundayo. Whether that lead holds up in the official half-year figures will be the first major question answered Wednesday.
Two other items will draw scrutiny. Novo has earmarked around DKK 55 billion in capital expenditures for 2026 to address supply constraints and expand global production capacity. And the company's 2026 revenue guidance — raised in May to a range of $42.39 billion to $46.24 billion — will be tested for durability. Management has already signaled the ZEUS outcome does not alter the previously communicated profit guidance, though a non-cash impairment charge will hit the third quarter.
The Legal Overhang
Investors also have a courtroom development to digest. A US class action accuses Novo Nordisk of misleading shareholders regarding the CagriSema study. A federal judge recently allowed parts of the case to proceed, ruling that plaintiffs had plausibly alleged misleading statements about tolerability and trial design. That is not a finding of securities fraud — merely a green light for litigation to continue. The company denies the allegations and says it will defend itself vigorously.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
What the Technicals Say
The stock currently sits almost exactly on its 50-day moving average of EUR 40.90. The 14-day RSI reads 41.8 — neither oversold nor overbought, suggesting the market has absorbed the ZEUS news without descending into panic. The EUR 40 level is widely viewed as critical support heading into the report.
Some analysts characterize 2026 as a transitional year for Novo, shaped by US pricing pressure and restructuring costs. Others point to the roughly 4.11 percent dividend yield and the momentum of oral therapies as stabilizing forces over the longer term. The shares had already lost about 40 percent of their value in the prior year before the May guidance raise offered some relief.
Two related studies — HERMES in heart failure patients and ARTEMIS following acute heart attacks — are still running, with results expected in the first half of 2027. Those readouts, along with Wednesday's earnings, will determine whether the current dip marks a buying opportunity or the beginning of a longer adjustment. For now, the support at EUR 40 holds the key.
Ad
Novo Nordisk Stock: New Analysis - 2 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
